Skip to main content

Table 2 SLEDAI-qualifying manifestations are associated with decreased ability to degrade chromatin from multiple sources

From: A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources

Manifestation

Total

NET

Primary necrotic chromatin

Secondary necrotic chromatin

n = 20/46

n = 41/25

n = 9/56

(% low/% normal)

(% low/% normal)

(% low/% normal)

Seizure

0

0/0

0/0

0/0

Psychosis

0

0/0

0/0

0/0

Organic brain syndrome

0

0/0

0/0

0/0

Visual disturbance

1

0/2.2

2.4/0

0/1.8

Lupus headache

0

0/0

0/0

0/0

Cerebrovascular accident

0

0/0

0/0

0/0

Vasculitis

5

15/4.4

4.9/12

11/7.2

Arthritis

8

10/13

12/12

11/13

Myositis

1

5/0

2.4/0

11/0*

Glomerulonephritis

    

Cylenduria

5

15/4.4

9.8/4

11/7

Hematuria

10

20/13

17/12

33/13

Proteinuria

13

30/15

22/16

44/16*

Pyuria

5

20/2.2*

9.8/4

22/5.4

Rash

10

15/15

15/16

11/16

Alopecia

9

20/11

20/4

22/13

Mucosal ulcers

8

15/11

17/4

22/11

Pleuritis

3

5/4.4

4.9/4

11/3.6

Pericarditis

0

0/0

0/0

0/0

Low complement

23

35/35

39/28

56/30

dsDNA antibodies

22

75/15***

41/20

67/27*

Fever

4

5/6.5

9.8/0*

0/7.1

Thrombocytopenia

0

0/0

0/0

0/0

Leukopenia

4

5/6.5

4.9/8

0/7.1

  1. Clinical manifestations during the time of sample collection were divided into groups according to their ability to degrade neutrophil extracellular traps (NETs), primary and secondary necrotic chromatin. Total patients with manifestation are indicated in the first column. For each source of DNA the total number of patients with low-versus-normal degrading ability are indicated and percent of patients with low-versus-normal degrading ability are indicated for each respective manifestation. Significance of differences were calculated using Pearson’s χ2 test: *p <0.05: and ***p <0.001; increased proportions in bold text